XML 59 R33.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Information (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2018
Segment Reporting [Abstract] |
Segment Information | 15. Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. The following table presents revenue for each reportable segment and Corporate:
| Three Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 29,720 |  |  | $ | 28,406 |
Medical | 3,916 |  |  | 3,418 |
Total segment revenue | 33,636 |  |  | 31,824 |
Corporate (1) | (3 | ) |  | (3 | )
Total revenue | $ | 33,633 |  |  | $ | 31,821 |
| Nine Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 89,786 |  |  | $ | 86,911 |
Medical | 11,684 |  |  | 10,107 |
Total segment revenue | 101,470 |  |  | 97,018 |
Corporate (1) | (10 | ) |  | (8 | )
Total revenue | $ | 101,460 |  |  | $ | 97,010 |
(1) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance. The results attributable to noncontrolling interests are recorded within segment profit. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; other income, net; interest expense, net; loss on extinguishment of debt; and provision for/(benefit from) income taxes. In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. We encourage our segments and corporate functions to identify investment projects that will promote innovation and provide future returns. As approval decisions for such projects are dependent upon executive management, the expenses for such projects are often retained at Corporate. Investment spending within Corporate was $7 million and $2 million for the three months ended March 31, 2018 and 2017, respectively, and $17 million and $4 million for the nine months ended March 31, 2018 and 2017, respectively. The following table presents segment profit by reportable segment and Corporate:
| Three Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 596 |  |  | $ | 611 |
Medical | 199 |  |  | 148 |
Total segment profit | 795 |  |  | 759 |
Corporate | (249 | ) |  | (154 | )
Total operating earnings | $ | 546 |  |  | $ | 605 |
| Nine Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 1,576 |  |  | $ | 1,682 |
Medical | 548 |  |  | 435 |
Total segment profit | 2,124 |  |  | 2,117 |
Corporate | (918 | ) |  | (436 | )
Total operating earnings | $ | 1,206 |  |  | $ | 1,681 |
The following table presents total assets for each reportable segment and Corporate at:
(in millions) | March 31, 2018 |  | June 30, 2017
Pharmaceutical | $ | 20,573 |  |  | $ | 21,848 |
Medical | 17,746 |  |  | 10,688 |
Corporate | 2,712 |  |  | 7,576 |
Total assets | $ | 41,031 |  |  | $ | 40,112 |
Revenue by Reportable Segment | The following table presents revenue for each reportable segment and Corporate:
| Three Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 29,720 |  |  | $ | 28,406 |
Medical | 3,916 |  |  | 3,418 |
Total segment revenue | 33,636 |  |  | 31,824 |
Corporate (1) | (3 | ) |  | (3 | )
Total revenue | $ | 33,633 |  |  | $ | 31,821 |
| Nine Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 89,786 |  |  | $ | 86,911 |
Medical | 11,684 |  |  | 10,107 |
Total segment revenue | 101,470 |  |  | 97,018 |
Corporate (1) | (10 | ) |  | (8 | )
Total revenue | $ | 101,460 |  |  | $ | 97,010 |
(1) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment | The following table presents segment profit by reportable segment and Corporate:
| Three Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 596 |  |  | $ | 611 |
Medical | 199 |  |  | 148 |
Total segment profit | 795 |  |  | 759 |
Corporate | (249 | ) |  | (154 | )
Total operating earnings | $ | 546 |  |  | $ | 605 |
| Nine Months Ended March 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 1,576 |  |  | $ | 1,682 |
Medical | 548 |  |  | 435 |
Total segment profit | 2,124 |  |  | 2,117 |
Corporate | (918 | ) |  | (436 | )
Total operating earnings | $ | 1,206 |  |  | $ | 1,681 |
Assets by Reportable Segment | The following table presents total assets for each reportable segment and Corporate at:
(in millions) | March 31, 2018 |  | June 30, 2017
Pharmaceutical | $ | 20,573 |  |  | $ | 21,848 |
Medical | 17,746 |  |  | 10,688 |
Corporate | 2,712 |  |  | 7,576 |
Total assets | $ | 41,031 |  |  | $ | 40,112 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration